Skip to main content

Table 1 Baseline characteristics of individuals who did and did not develop a recurrent SSTI during the study period

From: Recurrent skin and soft tissue infections in HIV-infected patients during a 5-year period: incidence and risk factors in a retrospective cohort study

Baseline variable No recurrent SSTI (n = 55) Had recurrent SSTI (n = 30) Total (n = 85)
Sex    
 Male 30 (65.2 %) 16 (34.8 %) 46 (54.1 %)
 Female 25 (64.1 %) 14 (35.9 %) 39 (45.9 %)
Sexual behavior    
Male 30 (65.2 %) 16 (34.8 %) 46
  Sex with men and women 6 (75.0 %) 2 (25.0 %) 8 (17.4 %)
  Sex with men 11 (64.7 %) 6 (35.3 %) 17 (36.7 %)
  Sex with women 13 (61.9 %) 8 (38.1 %) 21 (45.7 %)
Female 25 (64.1 %) 14 (35.9 %) 39
  Sex with women 1 (100 %) 0 (0 %) 1 (2.6 %)
  Sex with men 24 (63.2 %) 14 (36.8 %) 38 (97.4 %)
Mean initial age (sd) 40.7 (1.5) 40.1 (1.9) 40.5 (1.2)
Median initial CD4 (IQR) 363 (180–553) 351 (242–542) 353 (199–552)
Initial VL at time of first SSTI    
 <1000 28 (70.0 %) 12 (30.0 %) 40 (47.1 %)
 1000+ 27 (60.0 %) 18 (40.0 %) 45 (52.9 %)
IVDU history    
 No 49 (67.1 %) 24 (32.9 %) 73 (86.9 %)
 Yes 5 (45.4 %) 6 (54.6 %) 11 (13.1 %)
Inhaled drug use    
 No 41 (64.1 %) 23 (35.9 %) 64 (76.2 %)
 Yes 13 (65.0 %) 7 (35.0 %) 20 (23.8 %)
Methamphetamine use    
 No 54 (65.1 %) 29 (35.9 %) 83 (98.8 %)
 Yes 0 (0 %) 1 (100 %) 1 (1.2 %)
Incarceration    
 No 47 (61.8 %) 29 (38.2 %) 76 (90.5 %)
 Yes 7 (87.5 %) 1 (12.5 %) 8 (9.5 %)
Race    
 African-American 52 (67.5 %) 25 (32.5 %) 77 (91.7 %)
 Caucasian 2 (40.0 %) 3 (60.0 %) 5 (5.9 %)
 Hispanic 1 (50.0 %) 1 (50.0 %) 2 (2.4 %)
Educational status    
 Did not complete high school 5 (83.3 %) 1 (16.7 %) 6 (22.2 %)
 High school graduate 1 (33.3 %) 2 (66.7 %) 3 (11.1 %)
 Some college 8 (66.7 %) 4 (33.3 %) 12 (44.4 %)
 College graduate 4 (66.7 %) 2 (33.3 %) 6 (22.2 %)
Employment during follow-up    
 No 32 (64.0 %) 18 (36.0 %) 50 (59.5 %)
 Yes 22 (64.7 %) 12 (35.3 %) 34 (40.5 %)
Chronic skin disease    
 No 38 (69.1 % 17 (30.9 %) 55 (64.7 %)
 Yes 17 (56.7 %) 13 (43.3 %) 30 (35.3 %)
Hepatitis C    
 No 47 (64.4 %) 26 (35.6 %) 73 (85.9 %)
 Yes 8 (66.7 %) 4 (33.3 %) 12 (14.1 %)
Non-hepatitis liver disease    
 No 54 (67.5 %) 26 (32.5 %) 80 (94.1 %)
 Yes 1 (20.0 %) 4 (80.0 %) 5 (5.9 %)
Initial SSTI type    
 Abscess 28 (56.0 % 22 (44.0 %) 50 (58.8 %)
 Furuncle 20 (74.1 %) 7 (25.9 %) 27 (31.8 %)
 Cellulitis 7 (87.5 %) 1 (12.5 %) 8 (9.4 %)
Incision and drainage performed    
 No 41 (71.9 %) 16 (28.1 %) 57 (67.1 %)
 Yes 14 (50.0 %) 14 (50.0 %) 28 (32.9 %)
Initial SSTI S aureus    
 No 48 (68.6 %) 22 (31.4 %) 70 (82.4 %)
 Yes 7 (46.7 %) 8 (26.7 %) 15 (17.7 %)
Initial SSTI MRSA    
 No 50 (67.6 %) 24 (32.4 %) 74 (87.1 %)
 Yes 5 (45.5 %) 6 (54.5 %) 11 (12.9 %)
Initial SSTI Treatment    
 Combination therapy 11 (55.0 %) 9 (45.0 %) 20 (23.5 %)
 Beta-lactam 12 (60.0 %) 8 (40.0 %) 20 (23.5 %)
 Clindamycin 16 (76.2 %) 5 (23.8 %) 21 (24.7 %)
 Fluoroquinolone 4 (80.0 %) 1 (20.0 %) 5 (5.9 %)
 Trimethoprim- sulfamethoxazole 5 (62.5 %) 3 (37.5 %) 8 (9.4 %)
 Vancomycin 2 (100 %) 0 (0 %) 2 (2.3 %)
 None 3 (100 %) 0 (0 %) 3 (3.5 %)
 Unknown 2 (33.3 %) 4 (66.7 %) 6 (7.1 %)
Chlamydia since 2004    
 No 52 (64.2 %) 29 (35.8 %) 81 (95.3 %)
 Yes 3 (75.0 %) 1 (25.0 %) 4 (4.7 %)
Gonorrhea since 2004    
 No 54 (65.1 %) 29 (34.9 %) 83 (97.7 %)
 Yes 1 (50.0 %) 1 (50.0 %) 2 (2.3 %)
Syphilis since 2004    
 No 50 (63.3 %) 29 (36.7 %) 79 (92.9 %)
 Yes 5 (83.3 %) 1 (16.7 %) 6 (7.1 %)
Human papilloma virus (Clinical) since 2004    
 No 47 (65.3 %) 25 (34.7 %) 72 (84.7 %)
 Yes 8 (61.5 %) 5 (38.5 %) 13 (15.3 %)
Human papilloma virus (Pap) since 2004    
 No 45 (64.3 %) 25 (35.7 %) 70 (82.4 %)
 Yes 10 (66.7 %) 5 (33.3 %) 15 (27.6 %)
Trichomonas since 2004    
 No 47 (61.8 %) 29 (38.2 %) 76 (89.4 %)
 Yes 8 (88.9 % 1 (11.1 %) 9 (10.6 %)
Any sexually transmitted disease since 2004    
 No 29 (59.2 %) 20 (40.8 %) 49 (57.7 %)
 Yes 26 (72.2 %) 10 (27.8 %) 36 (42.4 %)
Pneumocystic jirovecii since 2004    
 No 54 (65.8 %) 28 (34.2 %) 82 (96.5 %)
 Yes 1 (33.3 %) 2 (66.7 %) 3 (3.5 %)
Non-tuberculous mycobacteria since 2004    
 No 53 (63.9 %) 30 (36.1 %) 83 (97.7 %)
 Yes 2 (100.0 %) 0 (0.0 %) 2 (2.4 %)
Cytomegalovirus since 2004    
 No 54 (64.3 %) 30 (35.7 %) 84 (98.8 %)
 Yes 1 (100.0 %) 0 (0.0 %) 1 (1.2 %)
Cryptococcus since 2004    
 No 53 (64.6 %) 29 (35.4 %) 82 (96.5 %)
 Yes 2 (66.7 %) 1 (33.3 %) 3 (3.5 %)
Initial TMP-SMX use    
 No 41 (65.1 %) 22 (34.9 %) 63 (74.1 %)
 Yes 14 (63.6 %) 8 (36.4 %) 22 (25.9 %)
Initial azithromycin use    
 No 48 (63.2 %) 28 (36.8 %) 76 (89.4 %)
 Yes 7 (77.8 %) 2 (22.2 %) 9 (10.6 %)
Initial HAART use    
 No 13 (52.0 %) 12 (48.0 %) 25 (29.4 %)
 Yes 42 (70.0 %) 18 (30.0 %) 60 (70.6 %)
Initial catheter presence    
 No 54 (65.9 %) 28 (34.1 %) 82 (96.5 %)
 Yes 1 (33.3 %) 2 (66.7 %) 3 (3.5 %)
Initial insurance Medicaid    
 No 16 (64.0 %) 9 (36.0 %) 25 (29.4 %)
 Yes 39 (65.0 %) 21 (35.0 %) 60 (70.6 %)
Initial cancer status    
 No 50 (63.3 %) 29 (36.7 %) 79 (92.9 %)
 Yes 5 (83.3 %) 1 (16.7 %) 6 (7.1 %)
Initial diabetes    
 No 48 (65.8 %) 25 (34.3 %) 73 (85.9 %)
 Yes 7 (58.3 %) 5 (41.7 %) 12 (14.1 %)
Initial ESRD status    
 No 48 (65.8 %) 25 (34.3 %) 73 (85.9 %)
 Yes 7 (58.3 %) 5 (41.7 %) 12 (14.1 %)